Additionally, Skp2 inhibitor (SZ-P1-41) treatment partially inhibits progression of bleomycin induced fibrosis, which suggests that a Skp2 inhibitor may be applicable to IPF therapy [87]. The gene discussed is SKP2; the disease is idiopathic pulmonary fibrosis.